Repeat in Biological Technology

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... stent had numerically lower incidences of repeat procedures to treat restenosis at two years as ... which had more than two times the risk of repeat procedures. The JACC article reported that both ... period. For the entire study population, the repeat revascularization rate per stent was 3.5 percent ...

Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601

... (DN). The data demonstrate that repeat administration of the drug is well tolerated in ... CMO. "First, we wanted to determine the safety of repeat dosing. Second, we evaluated dose schedule, ... the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild ...

Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis

... data from a Phase 1/2a study demonstrating that repeat administration with TRU-015 continues to ... upon re-treatment. Patients were eligible for repeat therapy at 24-week intervals. Thirty-eight ... time; pharmacokinetics; and immunogenicity of repeat doses of TRU-015 for RA following initial ...

FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting

... acute nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A ... nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, ... nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy. ...

Device That Clears Debris From Artery Aids Blood Flow in PCI

... (p equals 0.003). The combined rates of repeat heart attack, repeat procedure in the target ... grade and death, or a combination of death and repeat heart attack (p equals 0.001). The study team ... during PCI can reduce the risk of death and repeat heart attack, even one year later. Dr. Zijlstra ...

Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes

... Large inventories and a minimum five-year shelf-life allow researchers to repeat tests at future dates with no difference in product performance. Likewise, ... difficulty matching profiles, unknown enzymatic activities, inability to repeat experiments from the same donor and time restrictions - often mean ...

Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results

... customer base worldwide. Neptune expects revenue growth will be driven by repeat demand from existing customers and incoming demand from new customers from ... partners to rapidly secure substantially larger capacity in order to meet repeat and growing demand from existing and new customers worldwide. ...

Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year

... from prior year rental receivable reserve adjustments which did not repeat in the current year, while lower MEMS revenues partially offset this ... care, and prior year rental receivable reserve adjustments which did not repeat in the current year. Other Fourth Quarter Financial and Operational ...

Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees

... officials to solve crimes more rapidly and will also help prevent the repeat offenses committed by some criminals before they are convicted." ... officials to solve crimes more rapidly and will also help prevent the repeat offenses committed by some criminals before they are convicted, and the ...

REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart

... to inform parents of children with congenital heart defects about this new surgical device that reduces the risks associated with adhesions during repeat open-heart surgical procedures." About Adhesions Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, ...

Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.

... markets we serve." Nagarkatti continued, "We've reaffirmed our sales and profit expectations for all of 2009, believing that we can repeat our first half performance for the remainder of the year, even with a continuation of the challenging market conditions. We continued to invest in ...

Specialty Technical Consultants becomes Women-Owned Business Enterprise (WBE)

... worker safety and environmental challenges as business issues, rather than as engineering or legal obstacles. STC has a long list of well-satisfied repeat customers utilizing its EHS services, which include EHS management systems design and implementation, auditing, and performance improvement through ...

Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

... dermal fillers that are made of different kinds of natural or synthetic materials that are completely absorbed by the body over time and require repeat injections to maintain wrinkle correction. A skin test is required prior to treatment or approximately four (4) weeks ahead of time, to ensure a ...

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

... at the "Big A" to see the Angels play the Baltimore Orioles. At the Angels' game, Corey will again enter onto the field with other ALS patients to repeat a similar ceremony in the Angels' stadium and then spend the rest of the day with other ALS patients and advocates attending the game as well. ...

Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease

... are inherited. However, specific genetic factors relevant to the general population have been elusive. The PD gene is called leucine risk repeat kinase 2 (LRRK2) , which encodes a protein called dardarin, derived from the Basque word dardara, meaning tremor. Mutations in LRRK2 are a common ...

SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System

... death, stroke, myocardial infarction and revascularization) for the TAXUS Stent patients was 13 percent, driven primarily by a nine percent repeat revascularization rate. For CABG patients, the overall obstruction/occlusion ratio at 15 months was 16 percent, with six percent of grafts ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... vibration and warmth sensations compared with controls. In addition, combined data from almost 300 patients evaluated in two open-label, 1-year repeat treatment studies appeared to show no detrimental neurologic effects of repeated treatment with Qutenza. The most common adverse reactions observed ...

Encorium Group Signs Approximately $2.0 Million of New Business Contracts

... companies, today announced the signing of approximately $2.0 million of new business contracts, consisting of both new business contracts and repeat business to be conducted primarily in Europe. Revenue recognition will begin in the second quarter of 2009 on a proportional basis as services are ...

Virco Lab, Inc. Enters Into Collaboration with SmartGene, Inc. Enhancing HIV Resistance Test Services for Laboratories and Physicians

... testing when a patient is first diagnosed, whether or not antiretroviral (ARV) treatment is initiated immediately. If treatment is delayed, repeat testing at the time of treatment initiation should be considered. HIV resistance testing (RT) should also be used when changing a patient's regimen ...

Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session

... end systolic volumes, infarct size, reduction in subsequent MI's, and trends towards reduced deaths, admissions for heart failure and need for repeat vascularization. Strikingly, this analysis found a significant association between injected cell volume and improvement in ejection fraction that is ...

BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women

... should have their blood cholesterol levels checked at least once every five years. Diabetics and individuals with more than one risk factor should repeat the test more frequently. About BioIQ BioIQ ( www.bioiq.com ) develops and markets medical diagnostic solutions through corporate, ...

Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results

... data from its Phase 1 (SB-509-401) and Phase 2 (SB-509-601 and SB-509-701 Part A) clinical trials of SB-509 for DN. The studies demonstrated that repeat dosing of SB-509 is well-tolerated in subjects with DN. The SB-509-401 study demonstrated a statistically significant positive correlation of 2 or ...

OmniComm Systems, Inc. Experiences Record Year End Results - $18 Million in Signed Contracts for the Year 2008

... OMCM), a leader in integrated electronic data capture solutions for clinical trials, today announced record breaking results for 2008 in new and repeat business that exceeded original expectations. A record jump of 80% in contracts over 2007 clearly validates OmniComm's position as a major contender ...

Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results

... these studies." Recent Milestones In October, Trubion announced positive data for TRU-015 for RA from two re-treatment studies demonstrated that repeat administration with TRU-015 continued to produce persistent responses and significant improvements in RA signs and symptoms based on American College ...

Stem Cell Sciences Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc.

... experimental variability," said George Murphy, Senior Vice President of SCS LLC. "The deal is a further validation of the quality of SCS' media, and repeat use of CHDI's cell lines is expected to generate further revenue growth from ESGRO Complete(TM)." "The experience of Stem Cell Sciences in ...

Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter

... unit of certain incidents at the facility contrary to the Company's standard operating procedures. The FDA considered some of its observations to be repeat observations. The Company believes that the full warning letter, listing all of the observations, will be posted by the FDA shortly on its website at ...

Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research

... through gene-sequencing technologies. "For patients managing a brain-cancer diagnosis, access to multiple doctors in one location cuts down on repeat appointments and provides more efficient care," said David Newell, M.D., co-executive director of Swedish Neuroscience Institute. "Centers such as ...

Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles

... in routine multi-vessel PCI resulted in clinically-superior outcomes and reduced the composite of death, documented myocardial infarction, and repeat revascularization by 30 percent at one year. The study also demonstrated that adhering to an FFR-guided regimen for multi-vessel disease is cost ...

BioElectronics Corp. Announces $400,000 in New Orders From the Middle East

... are pleased that the new agent has hit the ground running and is finding wide marketing acceptance for our products. We look forward to significant repeat sales as the product is distributed throughout the territory," said Farid Tamimi V.P. of International Sales of BioElectronics Corporation. "There is ...

Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model

... HDAC inhibitors as a potential treatment for both Friedreich's ataxia and Huntington's disease." Huntington's disease is caused by a trinucleotide repeat expansion in the Huntington's disease gene (Htt) that results in production of a mutant misfolded protein that is unable to function correctly. ...

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing ...

Silence Therapeutics Patent Update

... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing ...

Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027

... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing ...

Organizational Changes at Silence Therapeutics

... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing ...

Silence Therapeutics Announces Successful Opposition of Glover Patent

... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing ...

WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology

... had provided services to more than 700 global clients, with coverage of pharmaceutical, biotechnology and medical devices. High proportion of repeat and referral customers is a testament to its focus on customer satisfaction and operation excellence," said Frost & Sullivan Leader of China ...

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry

... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing ...

AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women

... Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their physician. In clinical trials of AMITIZA (24 mcg) in patients with Chronic Idiopathic ...

Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis

... the anticoagulant effect of RB006 either completely or partially, depending on the level of dosing of RB007. The article, titled "A randomized, repeat dose, pharmacodynamic, and safety study of an antidote-controlled factor IXa inhibitor," was authored by Mark Y. Chan, Duke Clinical Research ...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

... AZ-001 produced a QT/QTc prolongation that would suggest an increased risk of cardiac arrhythmia. The Company recently completed a 28-day repeat dose inhalation study in dogs. Consistent with previous findings in shorter-term and higher dose studies, the Company observed ...